ArticleAmerican journal of translational research2016
Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Use of Diabetes Medications before and after a Heart Failure-Related Hospitalization among Nursing Home Residents.Journal of the American Medical Directors Association · 2024Article
- Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI.Acta diabetologica · 2024Article
- DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits.Military Medical Research · 2022Review
- Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure.Clinical diabetes : a publication of the American Diabetes Association · 2021Article
- Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials.International journal of environmental research and public health · 2019Article
- The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies.Heart failure reviews · 2018Review
- DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics.Heart failure reviews · 2018Review
- Effect of glucose-lowering therapies on heart failure.Nature reviews. Cardiology · 2018Review
- Clinical correlates and pharmacological management of Asian patients with concomitant diabetes mellitus and heart failure.Heart failure reviews · 2018Review
- Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.Journal of the American Heart Association · 2017Article
- The regulatory role of DPP4 in atherosclerotic disease.Cardiovascular diabetology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure, has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) assessing the cardiovascular risks of DPP4 inhibitors alogliptin and sitagliptin in 2013. Although there were no increased risks in composite cardiovascular outcomes, the SAVOR-TIMI 53 trial reported a 27% increase in hospitalization for heart failure in diabetic patients who received the DPP4 inhibitor saxagliptin. There has been substantial increase in knowledge on the heart failure effect of DPP4 inhibition since 2013. This review will summarize the role of the DPP4/incretin axis in heart failure and discuss the findings from recent large scale clinical trials assessing the effects of DPP4 inhibitors on heart failure.
Indexed as
Identifiers
27347354PMC4891459What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.